Kornimate/medical-research-clean huggingface dataset:
cervicothoracic junction mobilization versus muscle energy technique in chronic neck pain

Conditions: Chronic Mechanical Neck Pain

Summary: this study will be conducted to identify the difference between the effect of of cervicothoracic junction mobilization and autogenic muscle energy technique. on neck pain, cervical range of motion, cervical proprioception and neck disability in mechanical neck pain patients with cervicothoracic junction hypomobility.


Eligibility criteria:
inclusion criteria: * patients with a primary complaint of chronic neck pain (assessed by vas )for more than 3 months * subjects with pain provocation and reduced mobility at the ct junction segment (assessed by passive accessory intervertebral movements (paivms) and reduced mobility at cervical spine (assessed by crom device. * patients with age range from 18 to 45 years old. * patients with body mass index less than 30 kg/m2. * exclusion criteria: * previous spine surgery * pregnancy. * diabetic patients * hypertensive patients * patients were excluded if neck pain was associated with cervical radiculopathy * whiplash injuries or severe headaches * cervical spine fracture * vertebro-basilar insufficiency. * red flags suggesting of cancer, infection, vascular insufficiency * rheumatologic condition as mild systemic lupus erythematosus, poly-articular osteoarthritis, rheumatoid arthritis and advanced cervical spine degenerative diseases.

Keywords: chronic mechanical neck pain cervicothoracic junction mobilization autogenic muscle energy technique cervicothoracic junction hypomobility
reproductive outcome after sperm selection for intracytoplasmic sperm injection (icsi) using zona pellucida proteins

Conditions: Infertility, Male

Summary: the aim of this study is to analyze the effect of a sperm selection method by adhesion to partners' zona pellucida proteins on the assisted reproduction treatment (art) outcome parameters.

the success rate after treatment by in-vitro fertilisation (ivf) depends on the sperm selection process. classical sperm selection techniques are based on the spermatozoa morphology and motility, therefore are not able to measure the sperm ability to recognise the oocyte. furthermore it is known that semen samples showing higher adherence rate to zona pellucida have higher fertilisation potential than spermatozoa that fail to bind to zona proteins. there have been numerous reports on applying partner' native zona pellucida in sperm selection prior icsi. however, these studies imply the whole native zona pellucida, while this study will focus on the application of acid-solubilized zonae pellucidae. here in this study, the aim is to assess the fertilisation rate, the number and quality of the formed embryos, implantation and ongoing pregnancy success after sperm selection for icsi by their ability to adhere to immobilized zona pellucida proteins.

Eligibility criteria:
inclusion criteria: * clinical diagnosis for primary or secondary infertility * healthy females * clinical diagnosis for unexplained infertility * females between 20 and 45 years old. * males between 20 and 50 years old. * at least 3 retrieved oocytes per follicular puncture with at least 1 oocyte at germinal vesicle (gv) or metaphase i (mi) stage exclusion criteria: * presence of low quality oocytes * females with endometrial or ovarian infertility factor

Keywords: zona pellucida sperm selection icsi art outcomes
anal dilatation for infants and children with constipation

Conditions: Constipation

Summary: this study is to evaluate the effect of anal dilation in infants and children with constipation.


Eligibility criteria:
inclusion criteria: 1. infants and children with constipation 2. postoperative infants and children with hirschsprung's disease 3. good compliance exclusion criteria: 1. infants and children with constipation 2. poor compliance

Keywords: infants and children with constipation
efficacy and safety of dacomitinib in the treatment of skin squamous cell cancer

Conditions: Skin Squamous Cell Cancer

Summary: this is an open label, monocentric, uncontrolled phase ii trial with dacomitinib, a pan-her inhibitor, in unresectable or metastatic skin scc. her2 expression is common in skin scc, being reported with high rates, even if in small studies. coexpression of egfr, her2 and her3 is present in skin sccs but not in normal skin and it could be associated with the malignant phenotype. in this frame dacomitinib could play a role in the increase of the response rate.

the patients will assume dacomitinib 30 mg daily for the first 2 weeks. if the highest skin toxicity will be of grade \<2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days). if the highest skin toxicity will be grade \>2, then the patient will interrupt the treatment following the criteria for dose reduction. tumor evaluation will be performed at baseline and every other cycle. response will be assessed according to recist 1.1. the patient will continue to assume the study drug until disease progression, unacceptable toxicity or any medical condition that will suggest to stop the treatment for patient's safety

Eligibility criteria:
inclusion criteria: * signed informed consent to treatment * histological diagnosis of squamous cell carcinoma of the skin not amenable to surgical treatment with curative purposes or with clinical contraindication to surgery (examples of medical contraindications to surgery include but are not limited to: skin scc that has recurred in the same location after two or more surgical procedures and curative resection is deemed unlikely; anticipated substantial morbidity and/or deformity from surgery (e.g., removal of all or part of a facial structure, such as nose, ear, eyelid, eye; or requirement for limb amputation); anticipated difficulty in obtaining a curative resection due to the location of the tumour, the size of disease; anticipated difficulty in reconstructing the area that will be surgically removed; significant comorbidities that preclude the feasibility of a radical surgery * presence of measurable disease according to recist 1.1 * ecog performance status 0-2 * age≥ 18 years * for men and women in the fertile period: the use of birth control systems during treatment exclusion criteria: * previous treatment with tyrosine kinase inhibitors or monoclonal antibodies directed against egfr * any toxicity ctc grade\> 2 from previous treatments not yet resolved * pregnant or breastfeeding

Keywords: skin squamous cell cancer panher inhibitor dacomitinib
safety and feasibility of allogenic msc in the treatment of covid-19

Conditions: COVID-19; Sars-CoV2

Summary: coronavirus disease 2019 (covid-19) is spreading worldwide and has become a public health emergency of major international concern. currently, no specific drugs or vaccines are available. for severe cases, it was found that aberrant pathogenic t cells and inflammatory monocytes are rapidly activated and then producing a large number of cytokines and inducing an inflammatory storm. mesenchymal stem cells (mscs) have been shown to possess a comprehensive powerful immunomodulatory function. this study aims to investigate the safety and efficacy of intravenous infusion of mesenchymal stem cells in severe patients with covid-19.

coronavirus-19 disease (covid-19), caused by the sars-cov-2 virus, which occurs as a growing pandemic in early 2020 and currently represents an emergency state worldwide. several reports have shown that the first step in the pathogenesis of sars-cov-2 is the recognition of the angiotensin i converting enzyme (ace2) receptor by the virus. this ace2 receptor is widely distributed on the surface of human cells, especially as type ii alveolar cells and capillary endothelium, however bone marrow, lymph nodes, thymus and spleen are known as immune cells, such as t and lymphocytes. b and macrophages, are negatives to ace2. these results suggest that immunotherapy can be used to treat infected patients. however, an immunomodulatory capacity cannot be so strong, if just one or two major immunological factors used, as the virus can cause a "cytokine storm", such as il-2, il-6, il-7, gscf, ip10 , mcp1, mip1a and tnfα, followed by edema, gas exchange dysfunction, acute respiratory distress syndrome, cardiac injury and secondary infection that can lead to death. therefore, avoiding a "cytokine storm" may be the key to treating patients infected with sars-cov-2. mesenchymal stem cells (mscs), due to their potential for immunomodulatory activity, can have beneficial effects in preventing or attenuating the cytokine storm. because mscs have been widely used in cell therapy, from basic research to clinical trials. safety and efficacy have been clearly documented in several clinical trials, especially in immune-mediated inflammatory diseases, such as graft versus host disease (gvhd). the objective of the study is to verify the safety and feasibility of using allogeneic bone marrow mesenchymal stem cells in patients with sars-cov-2.

Eligibility criteria:
inclusion criteria: * laboratory confirmation of covid19 infection by reverse-transcription polymerase chain reaction (rt-pcr) * the patient or legal donor agrees to participate in the study and signs the informed consent. * patients with orange or red criteria according to the score proposed by liao et al (2020) exclusion criteria: * patient with pregnancy, are planning to become pregnant or breastfeeding * patients with malignant blood-borne diseases such as hiv or syphilis * not consenting for clinical trial * patients with other than orange or red criteria according to the score proposed by liao et al (2020)

Keywords: mesenchymal stromal cells covid-19 sars-cov2
sputum cytometry analysis in lung cancer screening after professional asbestos exposure

Conditions: Lung Neoplasms

Summary: workers exposed to asbestos are at high risk of lung cancer. medical follow-up of this population relies on repeated ct-scans which are more accurate for detection of peripheral lesions, and expose to x-rays and to risk of false-positives. analysis of sputum using automate cytometry may be of interest in this population, alone or in combination with ct-scan. an ancillary study will evaluate the interest of blood predictive biomarkers.


Eligibility criteria:
inclusion criteria: * high professional asbestos exposure * member of a former cohort recruited between 2000 and 2006 in caen, rouen and le havre (inclusion criteria: 50-75 years at the time of initial recruitment, high intermittent asbestos exposure \>= 1 year, or high discontinuous asbestos exposure \>=10 years). all the living members of the cohort will be contacted: a maximum of 1000 subjects is expected, probably less. * informed consent signed exclusion criteria: * personal history of lung cancer * refusal of the study protocol * uncontrolled asthma or lung failure

Keywords: lung cancer screening asbestos exposed workers sputum analysis automated cytometry predictive biomarkers
comparison of effects of tt with and without visual and auditory cues for freezing & gait patients with pd

Conditions: Parkinson Disease

Summary: to determine the comparison of effects of treadmill training with and without visual and auditory cues for freezing and gait in patients with parkinson's disease


Eligibility criteria:
inclusion criteria: * patient who are clinically diagnosed with parkinson disease. patients from both genders. patients with age between 45 years and above. patient with sufficient visual and auditory capacity to receive given cues will be included exclusion criteria: * patients with the history of neurological deficit other than pd. patients who need assistance for walking will be excluded. patient with any peripheral vascular disease will be excluded. patient with history of lower limb fracture.
a study to determine enzalutamide long-term safety and efficacy after anti-androgen therapy for crpc

Conditions: Castration Resistant Prostate Cancer (CRPC)

Summary: this is a prospective observational study to evaluate effectiveness and safety of enzalutamide for castration resistant prostate cancer (crpc) patients who decided to administer enzalutamide after anti-androgen therapy. crpc patients who are observed psa or disease progression after anti-androgen therapy and decided to administrate enzalutamide will dose the enzalutamide 160 mg orally once daily and observed the practical treatment. total research term is for 4 years, consists of 2-year case registration terms and 2-year observational terms.


Eligibility criteria:
inclusion criteria: 1. patients with histologically or cytologically confirmed prostate cancer. 2. patients who are receiving or received continuous androgen deprivation therapy using both gonadotropin-releasing hormone (gnrh) agonist and antagonist (medical castration), or both testicles removal by surgery (surgical castration). 3. castration resistant prostate cancer (crpc) patients who are observed disease progression after castration treatment and implied the treatment resistant. 4. crpc patients who conducted anti-androgen alternating therapy as shown below 1) and are observed one or more of disease progression shown as below 2) during or after the therapy and decided to administer enzalutamide. note 1) anti-androgen alternating therapy is defined as the therapy of flutamide administration after bicalutamide. note 2) disease progression criteria during or after anti-androgen alternating therapy ① psa progression during or after anti-androgen alternating therapy: psa increased more than 25% compare to the lowest test results after initial dose of anti-androgen alternating therapy (flutamide) and the increasing is more than 2ng/ml. ②confirmed disease progression of soft tissue lesion defined as recist v1.1. ③confirmed disease progression of bone lesion defined as 2 or more of new appearance of bone lesion on bone scintigraphy. 5. patients with the eastern cooperative oncology group (ecog) performance status 0-2 6. patients who have signed written informed consent to participate in this study exclusion criteria: 1. patients who is administering or have administration history of enzalutamide, abiraterone, docetaxel or cabazitaxel 2. patients with history of seizure or predisposing disease of seizure 3. patients with severe liver dysfunction 4. patients with a previous history of hypersensitivity to any component of drugs which will be administered in this study 5. patients who considered to be inappropriate for the study participation by the investigator
long-term survival and renal outcomes in critically ill patients after acute kidney injury: swedish multi-centre cohort study

Conditions: Acute Kidney Injury

Summary: the study evaluates how outcome varies among critically ill patients with and without acute kidney injury. data from the swedish intensive care register and other swedish national registers is used to compare how survival and post discharge renal function differ between critically ill patients with and without acute kidney injury.

background: acute kidney injury is common amongst intensive care patients and is associated with extremely high mortality and morbidity in terms of increased risk of developing chronic kidney disease (ckd) and end stage renal disease (esrd). patients with ckd are at increased risk of cardiovascular, cerebro-vascular disease and long term increased risk of death. those patients who progress to esrd have a 20% mortality risk per year in sweden. outcome after acute kidney injury in the swedish critical care population has never previously been described. method: this cohort study uses swedish national healthcare registers to investigate the epidemiology of acute kidney injury. the swedish intensive care register (sir) provides the population base, with data extraction between 2005 and 2011. the information obtained is cross-matched by the swedish board for health and welfare (social styrelsen) with other national registries. all data are returned anonymized and individual patients can not be identified in any way. additionally analysis is performed on a group and not on an individual basis. the key to this data is held by swedish board for health and welfare. the other national registries include the swedish cause of death register (dödsregister), the swedish renal register (svensknjurregistret) and the in and out-patients registers (öppen- slutenvårdsregister) these are used to obtain data on all cause mortality, co-morbidities, pre and post icu ckd and esrd. epidemiological methods are used to analyse the data. investigators aim to describe outcome in terms of long-term mortality (up to five years) and renal morbidity (incidence of ckd and esrd) in critically ill patients with and without de novo aki in sweden.

Eligibility criteria:
inclusion criteria: all first admissions of adult patients registered on the swedish intensive care register between january 1st 2005 and january 1st 2011. exclusion criteria: patients under 18. subjects with incomplete records. patients previously diagnosed with chronic kidney disease or end stage renal disease. -
evaluation of a transdiagnostic mobile app intervention among university students

Conditions: Emotion Regulation; Stress; Resilience; Depressive Symptoms; Anxiety

Summary: this study is a two-armed randomized controlled trial (rct) aimed at evaluating the effectiveness and adoption of a transdiagnostic mobile app intervention that focuses is on enhancing adaptive emotional regulation (er) skills among university students.

globally, an estimated 30% of university students struggle with mental health issues, primarily anxiety, depression, and substance abuse. recent trends have highlighted the potential of online interventions for accessible, low-threshold support in preventing these issues among this demographic. at erasmus university rotterdam (eur), a transdiagnostic mobile app is being developed as part of a student wellbeing program. this app provides a range of tools aimed at improving mental health by teaching students adaptive emotional regulation strategies. it incorporates exercises from various therapeutic modalities, addressing factors like negative thoughts, rumination, and prolonged negative emotions. delivered through a smartphone, the app includes 24 therapeutic exercises focusing on techniques such as enhancing positive emotions, mindfulness, cognitive defusion, cognitive restructuring, relaxation, breathing, and self-compassion. the present study is a 12-week two-armed rct study with outcomes assessed at the baseline, and three follow-ups at weeks 3, 8, and 12. it compares a group of distressed students with access to the mobile app intervention against a waitlist control group. the main goal of the study is to assess the impact of the intervention on stress symptoms and emotional regulation skills. the secondary outcomes of the study, include an evaluation of the intervention's impact on depression, anxiety symptoms, and students' resilience levels. lastly, the study examines the app's uptake, including engagement patterns and user experiences, and evaluates the real-life application of the skills learned through the app.

Eligibility criteria:
inclusion criteria: * willing to participate and provide informed consent * access to smartphone and internet * feels comfortable with english language for verbal and written communication and interaction with the app * scores \<13 on the perceived stress scale (pss-10) exclusion criteria: * scores \>20 on the patient health questionnaire (phq-9) * having a medical diagnosis of psychosis or bipolar disorder, severe clinical depression or anxiety disorder * undergoing psychopharmacological treatment or treatment with experimental drugs

Keywords: transdiagnostic intervention digital intervention mental health university students randomized controlled trial
optimal timing for embryo transfer for low responder patients

Conditions: Infertility

Summary: women undergoing in vitro fertilization (ivf) therapy, who are low responder and agree to enter the trial will be randomized to a study group, for whom embryo transfer will be done on the same day as oocyte aspiration and fertilization; and a control group for whom embryo transfer will be performed 48 to 72 hours later, as is the current accepted practice.


Eligibility criteria:
inclusion criteria: * patient undergoing ivf * number of mature oocytes equal to or lesser than the maximum number of embryos intended for transfer exclusion criteria: * patient nor consenting

Keywords: infertility low responder ivf embryo transfer
long-term effects of time to treatment in subarachnoid haemorrhage

Conditions: Spontaneous Subarachnoid Hemorrhage

Summary: for patients with spontaneous subarachnoid haemorrhage, it remains to be investigated if there is an association between the time from patients call the emergence medical coordination center to neurosurgical admission and long-term outcome. this is a retrospective cohort study with four-year followup. the primary aim is to determine if the time to neurosurgical admission is associated to labour marked affiliation and mortality after four years.


Eligibility criteria:
inclusion criteria: * spontaneous subarachnoid haemorrhage registered in the danish national patient register and confirmed by medical record review. * initially admitted to a hospital in the capital region of denmark between 1 january 2008 and 31 december 2014. exclusion criteria: * prior subarachnoid haemorrhage. * inhospital symptom onset.
efficacy and safety study of selinexor in relapsed or refractory peripheral t-cell lymphoma or cutaneous t-cell lymphoma

Conditions: Peripheral T-cell Lymphoma (PTCL); Cutaneous T-cell Lymphoma (CTCL)

Summary: this is a single-arm, multi-center, open-label phase 2 study of the sine™ compound selinexor given orally to patients with relapsed or refractory ptcl or ctcl. approximately 60 patients with relapsed or refractory ptcl or ctcl who meet the eligibility criteria and have none of the exclusion criteria will be enrolled to receive selinexor until either disease progression or intolerance has occurred.

this is a single-arm, multi-center, open-label phase 2 study of the sine™ compound selinexor given orally to patients with relapsed or refractory ptcl or ctcl. approximately 60 patients with relapsed or refractory ptcl or ctcl who meet the eligibility criteria and have none of the exclusion criteria will be enrolled to receive selinexor until either disease progression or intolerance has occurred. enrolled patients will be given selinexor as an oral fixed 60 mg dose (equivalent to \~35 mg/m²) on days 1 and 3 of weeks 1-4 of each 4-week cycle (total 8 doses per cycle). there is no maximum treatment duration. patients will receive supportive therapy to mitigate selinexor side effects, as well as best supportive care (bsc). patients enrolled under protocol versions \<3.0 were to receive selinexor orally, at a fixed dose of 60 mg (equivalent to \~35 mg/m²) on days 1 and 3 of weeks 1-3 of each 4-week cycle (total of 6 doses per cycle). selinexor was not taken during week 4. for all patients enrolled in this study (regardless of the protocol version) who continued onto cycle 3 and forward, the dose was to be increased by 20 mg to 80 mg (administered on days 1 and 3 of weeks 1-4), only after consultation with the sponsor's medical monitor.

Eligibility criteria:
inclusion criteria: * ecog performance status of ≤2. * relapsed or refractory disease to at least one prior systemic regimen. * measurable disease: according to international working group (iwg) guidelines for all patients with ptcl and according to ctcl response in skin consensus criteria for all patients with ctcl. * objective, documented evidence of disease progression on study entry. exclusion criteria: * known active central nervous system (cns) lymphoma. * active graft-versus-host disease after allogeneic stem cell transplantation. at least 4 months must have elapsed since completion of allogeneic stem cell transplantation. * unable to swallow tablets or malabsorption syndrome, disease significantly affecting gastrointestinal function.

Keywords: ptcl ctcl peripheral t-cell lymphoma cutaneous t-cell lymphoma karyopharm kpt-330 selinexor